Physician profile
Michael Fillers
NPI 1568206092
$2,323.05
in general payments reported to CMS, 2019-2025
38 companies · $1,727 in 2025
The $1,727 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $596 · 2025: $1,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,303 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,303.05 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $207.52 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $202.54 | 2024-2025 | Imfinzi, Lynparza, Calquence |
| Janssen Biotech, INC. | $152.23 | 2024-2025 | Talvey, Darzalex, Tecvayli |
| Pfizer INC. | $147.81 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $147.11 | 2024-2025 | |
| Daiichi Sankyo INC. | $123.10 | 2024-2025 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $113.31 | 2024-2025 | Opdivo |
| Genentech USA, INC. | $105.77 | 2024-2025 | Itovebi, Polivy, Alecensa |
| Array Biopharma INC | $102.83 | 2025 | Braftovi, Lorbrena, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $98.61 | 2024-2025 | Fruzaqla, Vpriv, Alunbrig |
| Merck Sharp & Dohme LLC | $87.80 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Incyte Corporation | $69.87 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Abbvie INC. | $65.91 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.51 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $50.24 | 2024-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fillers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.